SEC Form 4 · accession 0001144204-15-014088
Cellectar Biosciences, Inc. · CLRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Patrick Genn
Officer — VP of Business Development
Period of report
Feb 26, 2015
Accepted (ET)
Mar 4, 2015 · 7:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001279704
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $2.69 | Feb 26, 2015 | A | 10,000 | A | — | Feb 26, 2025 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1Option vests in equal quarterly increments over a period of three years from the date of grant.